A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53–HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By...

Full description

Bibliographic Details
Main Authors: Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Thérèse Valat, Masato Murakami, Stephan Ruetz, Daniel A Guthy, Caroline Rynn, Michael R Jensen, Marion Wiesmann, Joerg Kallen, Pascal Furet, François Gessier, Philipp Holzer, Keiichi Masuya, Jens Würthner, Ensar Halilovic, Francesco Hofmann, William R Sellers, Diana Graus Porta
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2015-05-01
Series:eLife
Subjects:
translational oncology
predictive signature
p53
HDM2
Online Access:https://elifesciences.org/articles/06498

Internet

https://elifesciences.org/articles/06498

Similar Items